The first c-Met ADC enters Phase III clinical trials

Article source: Medical Rubik's Cube Info

Recently, clinicaltrials showed that AbbVie's targeted c-Met antibody-conjugated drug Telisotuzumab Vedotin was registered for a phase III clinical trial, and it was the world's first c-Met ADC to enter a phase III clinical trial

American Clinical Trials Network

Medicine Rubik's Cube NextPharma

The study is an open-label, randomized, controlled, global phase III clinical trial, which aims to compare Telisotuzumab Vedotin (ABBV-399) vs docetaxel in previously treated c-Met+, EGFR wild-type, topical Efficacy and safety in patients with advanced/metastatic non-squamous non-small cell lung cancer

American Clinical Trials Network

The receptor tyrosine kinase MET gene is called Mesenchymal Epidermal Transformation Factor (MET), also known as Interstitial Epidermal Transformation Factor (c-Met) or Hepatocyte Growth Factor Receptor (HGFR)

When combined with its ligand HGF (hepatocyte growth factor), c-Met through dimerization and autophosphorylation, activates a series of downstream signaling pathways, and initiates related cell physiological and biochemical functions

c-Met related signal path

Telisotuzumab vedotin (ABBV-399), a first-in-class ADC developed by AbbVie, is composed of anti-c-Met humanized monoclonal antibody ABT-700 through a valine-citrulline linker (ABT- 700 vcMMAE) is conjugated to the cytotoxin monomethyl auristatin E (MMAE)

There are currently 4 c-Met ADCs that have entered clinical trials worldwide.

Note: The original text has been deleted